Pediatric Neurology & Rare Disease Breakthroughs

In this episode of MD Newsline, Dr. Jennifer Vermillion, assistant professor of neurology and pediatrics at the University of Rochester, shares her insights into pediatric movement disorders and rare neurodegenerative diseases, including Tourette syndrome and Batten disease (NCLs). She discusses how early diagnosis, genetic research, and advances in treatment—including gene therapy—are reshaping outcomes for children with these conditions. Dr. Vermillion also emphasizes the role of natural history studies, clinical trial design, and equitable access in improving care for patients and families. Episode Highlights: Recognizing Movement Disorders in Children Dr. Vermillion explains the spectrum of pediatric movement disorders, from benign behaviors like infant shuddering to chronic conditions like Tourette syndrome. She underscores the importance of understanding both the neurological and psychiatric aspects of these conditions, especially in children who also experience anxiety, OCD, or behavioral challenges. Tourette Syndrome: What We Know Now Tourette syndrome is often diagnosed in early childhood and may improve in adulthood for some. While there is no cure, new medications with fewer side effects have replaced older drugs like haloperidol. Dr. Vermillion highlights how improved understanding of brain circuitry and dopamine regulation is advancing treatment options. Batten Disease and the Role of Natural History Studies As a specialist in neuronal ceroid lipofuscinoses (NCLs), also known as Batten diseases, Dr. Vermillion explains the genetic basis of these rare disorders and the symptoms—seizures, cognitive decline, vision loss, and behavioral changes. She details her work on 20+ years of natural history data collection to support more effective trial design and the evaluation of emerging gene therapies. Barriers to Diagnosis and Access to Treatment Early diagnosis is crucial—especially when gene-based therapies may halt disease progression. Dr. Vermillion emphasizes the importance of newborn screening, standardized data collection across research centers, and the ethical challenges of delayed or denied insurance coverage for costly but life-altering treatments. The Future of Pediatric Rare Disease Care Dr. Vermillion is optimistic about the rapid advancements in rare disease therapy, particularly gene therapy and precision medicine. However, she calls for stronger advocacy, improved measurement tools, and more equitable systems to ensure all patients benefit from these scientific breakthroughs. Key Takeaway: With expanding access to genetic testing and emerging gene-based therapies, the landscape for pediatric movement and neurodegenerative disorders is evolving rapidly—highlighting the need for early diagnosis, collaborative research, and equitable access to care. Resources & Links: Website: MD Newsline Newsletter: Subscribe Here Connect with Dr. Jennifer Vermillion: https://www.urmc.rochester.edu/people/112360756-jennifer-a-vermilion Hosted on Acast. See acast.com/privacy for more information.